VolitionRx Limited announced the signing of a global supply agreement with a market leader in pet healthcare. Through Volition's supply agreement, the Company is engaged as a worldwide provider of the Nu.Q® Vet Cancer Test through its reference laboratory network for cancer indications in animal health. There are approximately 84 million pet dogs in the United States and just under 50% of dogs will have at least one veterinary care visit per annum which Volition believes will provide an incredible opportunity to screen those senior dogs (over 7 years) and breeds at risk of cancer from 4 years and upwards.